Literature DB >> 16645998

Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features.

D Singh-Grewal1, R Schneider, N Bayer, B M Feldman.   

Abstract

OBJECTIVE: To determine whether the disease course in systemic juvenile idiopathic arthritis (JIA) can be characterized as monophasic, polycyclic, or persistent, and to determine whether early clinical and laboratory characteristics can be used to predict the disease course and time to remission.
METHODS: Forty-five children with systemic JIA diagnosed between 1996 and 2000 were followed up with a standardized data collection protocol, including data on clinical and laboratory features (mean followup 4.9 years). Disease was considered inactive if the clinical and laboratory features were normal. Three definitions of remission were applied to classify disease course. Predictors of disease course were evaluated using multiple logistic regression. Predictors of time to remission were evaluated using Cox proportional hazards regression.
RESULTS: When applying a definition of remission requiring inactive disease while not receiving any medications for a period of 3 months, 42.2%, 6.7%, and 51.1% of the patients were classified as having monophasic, polycyclic, and persistent disease, respectively. Fever and active arthritis at 3 months (R2 = 0.42, area under the receiver operating characteristics curve [AUC] = 0.76) and an erythrocyte sedimentation rate (ESR) >26 mm/hour and corticosteroid use at 6 months (R2 = 0.49, AUC = 0.92) were predictive of a nonmonophasic course. Absence of active arthritis, an ESR of <26 mm/hour, and no requirement for corticosteroid therapy at 3 and 6 months were predictors of an earlier time to remission.
CONCLUSION: The disease course in systemic JIA can be characterized as monophasic, polycyclic, or persistent using a definition of remission requiring 3 months of inactive disease while not receiving any therapy. Features at 3 and 6 months are predictive of the disease course and time to remission.

Entities:  

Mesh:

Year:  2006        PMID: 16645998     DOI: 10.1002/art.21774

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  44 in total

1.  Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis.

Authors:  Peter A Nigrovic
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-17       Impact factor: 11.205

Review 2.  Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.

Authors:  Simon Tarp; Gil Amarilyo; Ivan Foeldvari; Robin Christensen; Jennifer M P Woo; Neta Cohen; Tracy D Pope; Daniel E Furst
Journal:  Rheumatology (Oxford)       Date:  2015-11-30       Impact factor: 7.580

3.  A Bullseye for Children With Systemic Juvenile Idiopathic Arthritis.

Authors:  Lauren A Henderson
Journal:  Arthritis Rheumatol       Date:  2019-05-27       Impact factor: 10.995

4.  Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.

Authors:  Hatice Ezgi Baris; Edwin Anderson; Betul Sozeri; Fatma Dedeoglu
Journal:  Clin Rheumatol       Date:  2018-09-20       Impact factor: 2.980

Review 5.  [Still's disease in children and adults].

Authors:  C M Hedrich; C Günther; M Aringer
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

6.  Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).

Authors:  Peter A Nigrovic; Timothy Beukelman; George Tomlinson; Brian M Feldman; Laura E Schanberg; Yukiko Kimura
Journal:  Clin Trials       Date:  2018-03-15       Impact factor: 2.486

7.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Rheum       Date:  2013-10

8.  Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis.

Authors:  Xuefeng B Ling; Kenneth Lau; Chetan Deshpande; Jane L Park; Diana Milojevic; Claudia Macaubas; Chris Xiao; Viorica Lopez-Avila; John Kanegaye; Jane C Burns; Harvey Cohen; James Schilling; Elizabeth D Mellins
Journal:  Clin Proteomics       Date:  2010-09-30       Impact factor: 3.988

9.  Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Authors:  Mark Gorelik; Ndate Fall; Mekibib Altaye; Michael G Barnes; Susan D Thompson; Alexei A Grom; Raphael Hirsch
Journal:  J Rheumatol       Date:  2013-05-15       Impact factor: 4.666

10.  [Remission in pediatric rheumatology].

Authors:  H-L Huppertz
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.